BioPharma Dive – AI / Data
Rocket gene therapy cleared by FDA for rare immune disorder
Though the therapy, Kresladi, isn’t seen as a big seller, its clearance is a step forward for a company that’s lost most of its value since 2021 amid several setbacks.